INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Delaney Mark E reported DGX

SVP & Chief Commercial Officer · QUEST DIAGNOSTICS INC · Common Stock

Side
A
Value
—
Shares
1,586
Price
—
Executed
Feb 18, 2026
Disclosed
Feb 20, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 18 executedFeb 20, 2026 disclosed

DGX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 21.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DGX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    39
    Carol D. MillerRSelf
    DGXQUEST DIAGNOSTICS INC
    Sale
    		SELL$15K – $50KMar 10, 2025Aug 13, 2026
    traded Mar 10, 2025
    		+521dHOUSE PTR

    Evidence

    39
    Julie JohnsonDJoint
    DGXQUEST DIAGNOSTICS INC
    Purchase
    		BUY$1,001 – $15KOct 30, 2025Aug 5, 2026
    traded Oct 30, 2025
    		+279dHOUSE PTR

    Evidence

    35
    Julie JohnsonDJoint
    DGXQUEST DIAGNOSTICS INC
    Sale
    		SELL$1,001 – $15KOct 30, 2025Aug 5, 2026
    traded Oct 30, 2025
    		+279dHOUSE PTR

    Evidence

    9
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    9,853 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$43K
    205 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$48K
    230 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    15
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Small acquisition
    		L$2,753
    15 sh
    		Jan 28, 2026Feb 20, 2026
    traded Jan 28, 2026
    		+23dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    7,332 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$54K
    259 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$53K
    252 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    17
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    2,135 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    19
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Small acquisition
    		L$2,936
    16 sh
    		Jan 28, 2026Feb 20, 2026
    traded Jan 28, 2026
    		+23dSEC FORM 4

    Evidence

    0
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$14K
    100 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    0
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$14K
    100 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    26
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Open-market sale · 10b5-1 plan
    		SELL$1.49M
    7,946 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    8
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$1.13M
    7,846 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    20
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$1.13M
    7,846 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001955265-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 18, 2026
    Published
    Feb 20, 2026
    Ingested by INSIDER
    Nov 5, 04:15 UTC
    Last re-read
    Nov 5, 04:15 UTC

    Extracted facts

    Filer
    Delaney Mark E
    Role
    SVP & Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    QUEST DIAGNOSTICS INC
    Ticker
    DGX
    Shares
    1,586
    Price per share
    $0
    Execution date (reported)
    Feb 18, 2026
    Owned after transaction
    9,116 shares
    Days from execution to publication
    2

    What this establishes

    Delaney Mark E filed this Form 4 reporting a grant or award of DGX on Feb 18, 2026. It became public on Feb 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP & Chief Commercial Officer
    Delaney Mark Ecik:0001955265
    Issuer
    QUEST DIAGNOSTICS INCcik:0001022079

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.